The Relationship between the dose of Epoetin Beta Pegol for treatment of renal anemia and renal prognosis in CKD Patients
Not Applicable
- Conditions
- renal anemia in CKD patients not on hemodialysis
- Registration Number
- JPRN-UMIN000011237
- Lead Sponsor
- Toda Central General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Anemia for other reasons than the renal anemia: 1) Iron deficiency (Serum ferritin <100 ng/mL and transferrin saturation <20%) 2) Vitamin B12 deficiency 3) Folic acid deficiency 4) Apparent hemorrhagic lesion 5) hematologic disease (e.g. leukemia, malignant lymphoma, myelodysplastic syndrome, aplastic anemia) 6) Disease associated with chronic inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease) 7) Under myelosuppressive therapy (immunosuppressive therapy, chemotherapy or radiotherapy) (2) Under treatment for malignansy and severe infection (3) Post renal transplant patient (4) Hypersensitivity to epoetin beta pegol (5) Pregnancy or lactating (6) eGFR <6.0 mL/min/1.73 m2
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Renal prognosis 1) time to doubling of serum creatinine level 2) time to entry in a hemodialysis 3) time to decreace in eGFR to less than 6.0 mL/min/1.73 m2
- Secondary Outcome Measures
Name Time Method